No MS uplift

Genzyme Corp. presented long-term follow-up data from a Phase II trial of alemtuzumab to treat multiple sclerosis that the company may hope will help sway shareholders against sanofi-aventis Group's $69-per-share tender offer for the biotech.

However, the story may be harder to sell now that oral MS agents are hitting the market. Indeed, Genzyme was off $0.17 to $72.43 on Thursday following the data presentation, and was off $0.56 to $72.19 on the week...